BRPI0810179B8 - composições de oligoguluronato e galacturonato e usos dos mesmos - Google Patents
composições de oligoguluronato e galacturonato e usos dos mesmosInfo
- Publication number
- BRPI0810179B8 BRPI0810179B8 BRPI0810179A BRPI0810179A BRPI0810179B8 BR PI0810179 B8 BRPI0810179 B8 BR PI0810179B8 BR PI0810179 A BRPI0810179 A BR PI0810179A BR PI0810179 A BRPI0810179 A BR PI0810179A BR PI0810179 B8 BRPI0810179 B8 BR PI0810179B8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- galacturonate
- oligoguluronate
- guluronate
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 title abstract 3
- 238000006116 polymerization reaction Methods 0.000 abstract 2
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 abstract 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0707096.4A GB0707096D0 (en) | 2007-04-12 | 2007-04-12 | Method |
PCT/GB2008/001287 WO2008125828A2 (en) | 2007-04-12 | 2008-04-11 | Oligo-guluronate and galacturonate compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0810179A2 BRPI0810179A2 (pt) | 2014-12-30 |
BRPI0810179B1 BRPI0810179B1 (pt) | 2019-12-10 |
BRPI0810179B8 true BRPI0810179B8 (pt) | 2021-05-25 |
Family
ID=38116633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0810179A BRPI0810179B8 (pt) | 2007-04-12 | 2008-04-11 | composições de oligoguluronato e galacturonato e usos dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (1) | US8841279B2 (pt) |
EP (2) | EP2500025B1 (pt) |
JP (2) | JP5649443B2 (pt) |
KR (2) | KR101472245B1 (pt) |
CN (1) | CN101711159B (pt) |
AU (1) | AU2008237710B2 (pt) |
BR (1) | BRPI0810179B8 (pt) |
CA (2) | CA2683914C (pt) |
DK (2) | DK2155211T3 (pt) |
EA (1) | EA018776B1 (pt) |
ES (2) | ES2655102T3 (pt) |
GB (1) | GB0707096D0 (pt) |
MX (2) | MX352972B (pt) |
WO (1) | WO2008125828A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
CN104189908B (zh) * | 2007-11-27 | 2017-01-11 | 阿尔吉法玛公司 | 包含藻酸盐低聚物的产品、包含无生命表面的产品和清创组合物 |
GB0904942D0 (en) * | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
GB0904941D0 (en) | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
US9018158B2 (en) | 2009-06-03 | 2015-04-28 | Algipharma As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
GB0909557D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Anti-microbial alginate oligomers |
GB0909529D0 (en) | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
JO3676B1 (ar) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها |
GB201116010D0 (en) | 2011-09-15 | 2011-10-26 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
GB201322777D0 (en) | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
JP2017501221A (ja) * | 2013-12-23 | 2017-01-12 | ノルウェージャン ユニバーシティ オブ サイエンス アンド テクノロジー(エヌティーエヌユー) | がん治療におけるオリゴウロン酸塩の使用 |
KR20160119259A (ko) * | 2014-02-28 | 2016-10-12 | 알지파마 에이에스 | 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도 |
FR3024358B1 (fr) * | 2014-08-01 | 2017-11-10 | Soc De Courtage Et De Diffusion Codif Int | Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau. |
GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
GB201504878D0 (en) * | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
AU2018205823A1 (en) | 2017-01-03 | 2019-07-18 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
CN110461338A (zh) | 2017-03-28 | 2019-11-15 | 北卡罗来纳大学查佩尔希尔分校 | 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法 |
AU2019231712A1 (en) | 2018-03-06 | 2020-10-15 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
GB201812473D0 (en) | 2018-07-31 | 2018-09-12 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
WO2020139857A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
US11684597B2 (en) | 2019-01-28 | 2023-06-27 | The United States Of America As Represented By The Secretary Of The Army | Administration of tailored feedstock to increase nitro-containing amphenicol antibiotic susceptibility |
GB201908639D0 (en) | 2019-06-17 | 2019-07-31 | Algipharma Ipr As | Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297511A (pt) | 1956-12-20 | |||
FR7576M (pt) | 1968-03-27 | 1970-01-05 | ||
HU172831B (hu) | 1976-03-31 | 1978-12-28 | Egyt Gyogyszervegyeszeti Gyar | Sposob poluchenija kompleksov oligo- i poligalakturonnyk kislot s ionami zhiznenno vazhnykh metallov |
JPS6176413A (ja) | 1984-09-21 | 1986-04-18 | Junzo Sunamoto | 吸水性高分子によりカプセル化されたリポソ−ムの製造法 |
DD268865A1 (de) | 1987-01-16 | 1989-06-14 | Adw Ddr | Verfahren zur herstellung eines pharmazeutischen praeparates |
US4898852A (en) | 1987-06-02 | 1990-02-06 | Walsh William E | Cyclopolgalcturonic acid composition and treatment |
US4855128A (en) | 1988-01-14 | 1989-08-08 | Warner-Lambert Company | Saccharide inhibition of dental plaque |
JP2641472B2 (ja) | 1988-01-30 | 1997-08-13 | 日本レダリー株式会社 | 感染症治療剤 |
US5459054A (en) | 1989-12-05 | 1995-10-17 | Neocrin Company | Cells encapsulated in alginate containing a high content of a- l- guluronic acid |
EP0502949A4 (en) | 1989-12-05 | 1993-02-24 | Trancel Corporation | Homologous guluronic acid alginate coating composition for in-vivo application and implantation and method of using same |
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
US5166137A (en) | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
US5460957A (en) | 1992-04-28 | 1995-10-24 | Maruha Corporation | Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate |
HU213872B (en) | 1993-09-08 | 1997-11-28 | Mta Koezponti Kemiai Kutato In | Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds |
DE4330773A1 (de) | 1993-09-10 | 1995-03-16 | Laevosan Gmbh & Co Kg | Blockierung der Anlagerung von Keimen an menschliche Zellen |
JP2828391B2 (ja) | 1993-10-29 | 1998-11-25 | 東燃株式会社 | オリゴ糖を表面に有するリポソーム |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
AU723170B2 (en) | 1995-10-19 | 2000-08-17 | Bio-Origyn Llc | Methods and compositions to improve germ cell and embryo survival and function |
JP3512553B2 (ja) | 1996-01-30 | 2004-03-29 | ポーラ化成工業株式会社 | 便秘抑制剤及びそれを含有する組成物 |
FR2747045B1 (fr) | 1996-04-05 | 1998-06-26 | Hooreman Michel | Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin |
NO305441B1 (no) | 1996-07-12 | 1999-05-31 | Norsk Hydro As | Anvendelse av G-blokk polysakkarider |
AU740111B2 (en) | 1996-09-27 | 2001-11-01 | Jagotec Ag | Hyaluronic drug delivery system |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
KR100219918B1 (ko) | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
WO1999034543A1 (en) * | 1997-12-31 | 1999-07-08 | Sony Corporation | Coded data output device and method |
JP3932679B2 (ja) * | 1998-07-21 | 2007-06-20 | セイコーエプソン株式会社 | ポリグルロン酸の製造法 |
US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
CA2382259A1 (en) | 1999-08-26 | 2001-03-08 | Governors Of The University Of Alberta | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
JP2001155905A (ja) * | 1999-11-24 | 2001-06-08 | Nec Corp | 半導体装置およびトリミング方法ならびに記録媒体 |
US7785625B2 (en) | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
KR100501584B1 (ko) | 2000-02-03 | 2005-07-18 | (주)케이비피 | 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품 |
DE10006989A1 (de) | 2000-02-16 | 2001-08-23 | Nutricia Nv | Antiadhäsive Kohlenhydratmischung |
US6706276B2 (en) | 2000-03-07 | 2004-03-16 | Rush-Presbyterian-St. Luke's Medical Center | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
WO2001072278A2 (en) | 2000-03-30 | 2001-10-04 | Generex Pharmaceuticals Inc. | Method for administering insulin to the buccal region |
DE10019076A1 (de) | 2000-04-06 | 2001-10-18 | Lang Christine | Verwendung von Polygalakturoniden als Lebensmittelzusatzstoffe |
JP2002338493A (ja) | 2000-10-23 | 2002-11-27 | Genaera Corp | ムチン合成インヒビター |
DE10057976B4 (de) | 2000-11-22 | 2005-02-03 | Südzucker AG Mannheim/Ochsenfurt | Verfahren zur Herstellung von Pektinhydrolyseprodukten |
US6440314B1 (en) * | 2001-01-03 | 2002-08-27 | Vulcan Chemical Technologies, Inc. | Method for destroying chlorite in solution |
ITMI20010347A1 (it) | 2001-02-21 | 2002-08-21 | Grisotech S A | Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale |
US6610331B1 (en) | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
JP2005145885A (ja) | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | アルギン酸オリゴマーからなる免疫機構賦活剤 |
WO2005089722A1 (en) | 2004-03-12 | 2005-09-29 | Biodel, Inc. | Rapid acting drug delivery compositions |
JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
JP2006028041A (ja) | 2004-07-13 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 核酸含有ナノ粒子 |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
US7621036B2 (en) | 2005-06-21 | 2009-11-24 | Cardiomems, Inc. | Method of manufacturing implantable wireless sensor for in vivo pressure measurement |
EP1745705A1 (en) | 2005-07-20 | 2007-01-24 | N.V. Nutricia | Process for preparing uronic acid oligosaccharides by extrusion |
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
MX2008004962A (es) | 2005-10-21 | 2009-03-02 | Living Cell Products Pty Ltd | Sistema de encapsulamiento. |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
WO2008137114A1 (en) | 2007-05-04 | 2008-11-13 | University Of Hawai'i | Methods and compositions for targeted delivery of gene therapeutic vectors |
EP2276727A1 (en) | 2008-05-19 | 2011-01-26 | The University of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
-
2007
- 2007-04-12 GB GBGB0707096.4A patent/GB0707096D0/en not_active Ceased
-
2008
- 2008-04-11 DK DK08736951.8T patent/DK2155211T3/en active
- 2008-04-11 EP EP12161928.2A patent/EP2500025B1/en active Active
- 2008-04-11 BR BRPI0810179A patent/BRPI0810179B8/pt not_active IP Right Cessation
- 2008-04-11 DK DK12161928.2T patent/DK2500025T3/en active
- 2008-04-11 US US12/595,818 patent/US8841279B2/en active Active
- 2008-04-11 ES ES12161928.2T patent/ES2655102T3/es active Active
- 2008-04-11 WO PCT/GB2008/001287 patent/WO2008125828A2/en active Application Filing
- 2008-04-11 EP EP08736951.8A patent/EP2155211B1/en active Active
- 2008-04-11 JP JP2010502572A patent/JP5649443B2/ja active Active
- 2008-04-11 CN CN2008800196645A patent/CN101711159B/zh active Active
- 2008-04-11 CA CA2683914A patent/CA2683914C/en active Active
- 2008-04-11 MX MX2014005931A patent/MX352972B/es unknown
- 2008-04-11 ES ES08736951.8T patent/ES2553962T3/es active Active
- 2008-04-11 KR KR1020137022922A patent/KR101472245B1/ko active IP Right Grant
- 2008-04-11 AU AU2008237710A patent/AU2008237710B2/en active Active
- 2008-04-11 KR KR1020097023647A patent/KR101336459B1/ko active IP Right Grant
- 2008-04-11 MX MX2009010889A patent/MX2009010889A/es active IP Right Grant
- 2008-04-11 EA EA200901299A patent/EA018776B1/ru unknown
- 2008-04-11 CA CA2817754A patent/CA2817754C/en active Active
-
2014
- 2014-03-05 JP JP2014042608A patent/JP2014129401A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0810179B8 (pt) | composições de oligoguluronato e galacturonato e usos dos mesmos | |
BR0111381A (pt) | Composições, kits e métodos para promover benefìcios definidos a saúde | |
BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
BRPI0509217B8 (pt) | derivados de oligossacarídeo alginato, seu uso e seu processo de preparação, e composição farmacêutica | |
BRPI0409890A (pt) | processo para a produção de um gel de polissacarìdeo reticulado, gel de polissacarìdeo reticulado substancialmente resistente à degradação de hialuronidase, composição farmacêutica, método para o tratamento ou a prevenção de um distúrbio ou uma condição selecionada do grupo que consiste em aumento de tecido, artrite, aderências de tecidos, capacidade imunogênica, doenças da mucosa, condições dermatológicas, condições oftalmológicas, condições hormonais, condições de lubrificação das juntas e condições cosméticas, em um indivìduo com necessidade do mesmo e uso de um gel | |
Lyte | Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori | |
BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
BR112012002639A2 (pt) | métodos e composições para melhorar a saude gastrintestinal | |
CN108158876B (zh) | 一种皮肤保湿修护组合物及其制备方法 | |
BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
BR112012012210B8 (pt) | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano | |
Takahashi et al. | A decrease in the molecular weight of hyaluronic acid in synovial fluid from patients with temporomandibular disorders | |
BRPI0912842A8 (pt) | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina | |
MY149505A (en) | Hyaluronic acid binary mixtures and therapeutic use thereof | |
BRPI0707488B8 (pt) | método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável | |
BRPI0511355A (pt) | composição para aplicação tópica na pele de mamìferos, seu uso, métodos para confecção de composições, método para o tratamento da psorìase e método para o tratamento do eczema | |
BR0116952A (pt) | Fotosensibilizador e método para a produção do mesmo | |
BR9811923A (pt) | Compostos possuindo atividade neuronal | |
BR112022018645A2 (pt) | Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide | |
BR0314335A (pt) | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade | |
BR9904613A (pt) | Utilização de uma goma de silicone, composição tópica e utilização de uma composição | |
BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
BRPI0406477A (pt) | Composição, agente de tratamento de óleo, e, métodos de produção de uma composição e de tratamento de óleo | |
BRPI0801239A2 (pt) | uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B25G | Requested change of headquarter approved |
Owner name: NTNU TECHNOLOGY TRANSFER AS (NO) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |